Hikma Pharmaceuticals (LON:HIK) Share Price Crosses Above 200-Day Moving Average of $1,865.76

Hikma Pharmaceuticals PLC (LON:HIK) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,865.76 ($23.44) and traded as high as GBX 1,977 ($24.83). Hikma Pharmaceuticals shares last traded at GBX 1,960 ($24.62), with a volume of 289,757 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently commented on HIK shares. Barclays reissued an “equal weight” rating and set a GBX 2,000 ($25.12) price objective on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 ($25.12) price objective on shares of Hikma Pharmaceuticals in a report on Thursday, April 25th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Hikma Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 2,068.75 ($25.99).

Hikma Pharmaceuticals Price Performance

The firm has a fifty day moving average of GBX 1,880.72 and a 200 day moving average of GBX 1,865.76. The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. The company has a market capitalization of £4.35 billion, a P/E ratio of 2,882.35, a P/E/G ratio of 2.38 and a beta of 0.44.

Hikma Pharmaceuticals Increases Dividend

The business also recently declared a dividend, which was paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st were paid a $0.47 dividend. The ex-dividend date of this dividend was Thursday, March 21st. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a dividend yield of 1.86%. Hikma Pharmaceuticals’s payout ratio is currently 8,382.35%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.